Repositorio Dspace

Immune Trajectories After Switch to Long-Acting Cabotegravir Plus Rilpivirine in the RELATIVITY Cohort

Mostrar el registro sencillo del ítem

dc.contributor.author Troya, Jesus
dc.contributor.author Cabello-Clotet, Noemi
dc.contributor.author Bernardino, José-Ignacio
dc.contributor.author Galindo, María-José
dc.contributor.author Martínez, Rosa-María
dc.contributor.author Martin, Juan
dc.contributor.author Aleman, María-Remedios
dc.contributor.author Torralba, Miguel
dc.contributor.author Fanjul, Francisco
dc.contributor.author Fariñas, María-Carmen
dc.contributor.author Rodríguez, Adrián
dc.contributor.author Crusells, María-José
dc.contributor.author Calzado, Sonia
dc.contributor.author Pérez-Serrano, Javier
dc.contributor.author Hidalgo-Tenorio, Carmen
dc.contributor.author Morano, Luis-Enrique
dc.contributor.author Vinuesa, David
dc.contributor.author Bernal-Morell, Enrique
dc.contributor.author Poquet-Catala, Inmaculada
dc.contributor.author Pernas-Pardavila, Hadrian
dc.contributor.author Tiraboschi, Juan
dc.contributor.author Corps, Diana
dc.contributor.author Vivancos, María-Jesús
dc.contributor.author Buzon-Martin, Luis
dc.date.accessioned 2026-11-11T09:05:31Z
dc.date.available 2026-11-11T09:05:31Z
dc.date.issued 2026-09-29
dc.identifier.citation Troya J, Cabello-Clotet N, Bernardino JI, Galindo MJ, Martínez RM, Martín J, et al. Immune Trajectories After Switch to Long-Acting Cabotegravir Plus Rilpivirine in the RELATIVITY Cohort. Open Forum Infectious Diseases. 29 de septiembre de 2026;13(10):ofag583. doi:10.1093/ofid/ofag583
dc.identifier.issn 2328-8957
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29173
dc.description.abstract Background Immune and virological trajectories after switching to long-acting cabotegravir plus rilpivirine (CAB+RPV LA) remain incompletely characterized in routine care settings. Methods We analyzed virologically suppressed adults switching to CAB+RPV LA in the Spanish multicenter RELATIVITY cohort. Paired CD4+, CD8+, and CD4/CD8 measurements were assessed at approximately 12 and 24 months and at the last available immune assessment. Analyses used a 1.0 ratio threshold and incorporated longitudinal HIV-1 RNA, recorded geographic origin, pre-switch suppression duration, and immediate pre-switch antiretroviral therapy. Results Among 3349 participants, the last paired-ratio assessment (n = 2929) occurred at a median of 22 months (IQR, 16-27). Median changes were ?7 cells/mm3 (IQR, ?138 to +117; n = 2992) for CD4+ T-cell count, ?60 cells/mm3 (IQR, ?214 to +75; n = 2941; P < .001) for CD8+ T-cell count, and +0.07 (IQR, ?0.05 to +0.20; n = 2929; P < .001) for the CD4/CD8 ratio. Baseline CD4/CD8 <1.0 was independently associated with greater ratio increase (adjusted beta, +0.060; 95% CI, +.030 to +.090; P < .001). Longer pre-switch suppression and any post-switch HIV-1 RNA ?50 copies/mL were associated with smaller ratio increases. Adjudicated virological failure occurred in 28/3349 (0.8%). Findings persisted among participants with all recorded post-switch HIV-1 RNA values <50 copies/mL and after excluding protocol-defined virological failure. Conclusions During effective CAB+RPV LA maintenance, CD4+ T-cell counts showed no meaningful change, while a modest decline in CD8+ T-cell counts was accompanied by a small CD4/CD8 ratio increase. These descriptive changes are compatible with continued immune evolution during sustained suppression and do not establish a CAB+RPV-specific effect or justify additional routine T-cell-subset monitoring.
dc.language.iso eng
dc.publisher OXFORD UNIV PRESS INC
dc.rights Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.title Immune Trajectories After Switch to Long-Acting Cabotegravir Plus Rilpivirine in the RELATIVITY Cohort
dc.type info:eu-repo/semantics/article
dc.relation.publisherversion https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofag583/8881809
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1093/ofid/ofag583
dc.journal.title Open Forum Infectious Diseases


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta